Masayuki Ohnaka

Comparative effectiveness of three treatment strategies for submacular hemorrhage secondary to age-related macular degeneration

Masato Ishino, Katsuaki Miki, Toshiki Oka, Akiko Miki et autres

Abstract We aimed to compare the effectiveness of three treatment strategies for extensive submacular hemorrhage (SMH) secondary to age-related macular degeneration (AMD): intravitreal anti-vascular endothelial growth factor (VEGF) monotherapy, anti-VEGF combined with sulfur hexafluoride (SF₆) gas tamponade, and triple therapy consisting of …

jp (code pays fourni par la source)

Association Between Repeated Prophylactic Antimicrobial Eye Drop Use and Reduced Antimicrobial Susceptibility in Conjunctival and Nasal Commensal Bacteria

Ryo Tomemori, Kaoru Araki‐Sasaki, Tatsuya Kanagawa, Masayuki Ohnaka et autres

Background/Objectives: The objective of this study was to clarify changes in the antimicrobial susceptibility of commensal bacteria in the conjunctival sac and nasal cavity associated with repeated use of prophylactic antimicrobial eye drops during intravitreal anti-vascular endothelial growth factor injections. Methods: Patients …

jp (code pays fourni par la source)

Real-world outcomes after switching to faricimab in treatment-resistant diabetic macular edema: A 1-year observational study with choroidal thickness assessment

Ryo Tomemori, Hidetsugu Mori, Mari Tanaka, Tatsunori Kiriishi et autres

Approximately 40% of diabetic macular edema (DME) cases are resistant to conventional anti-vascular endothelial growth factor (VEGF) therapy. Although faricimab (an antibody against VEGF-A and angiopoietin-2 [Ang-2]) has shown efficacy in treatment-naïve DME, real-world evidence on switching strategies in resistant cases remains …

jp (code pays fourni par la source)

Differential Roles of VEGFA and FGF2 in Vascular Maturation and Regression of Laser-Induced Choroidal Neovascularization

Yuichi Yamamoto, Haruhiko Yamada, Hidetsugu Mori, Yuki Hattori et autres

jp (code pays fourni par la source)

Reduced-fluence photodynamic therapy versus placebo for central serous chorioretinopathy (REPLAY trial): rationale and study protocol of a pivotal double-blind randomised controlled trial

Masahiro Miyake, Ayako Takahashi, Takayuki Baba, Ichiro Maruko et autres

INTRODUCTION: Chronic central serous chorioretinopathy (CSC) can cause progressive and permanent vision loss. Although photodynamic therapy (PDT) is a primary treatment option globally, it is not approved for CSC worldwide, limiting therapeutic access. The REPLAY trial is a phase III, investigator-initiated trial …

jp (code pays fourni par la source)

Impact of Reticular Pseudodrusen on Clinical and Ocular Characteristics and Progression Rate of Geographic Atrophy in Japanese Patients

Naoko Ueda‐Arakawa, Yukiko Sato, Masahiro Miyake, Ayako Takahashi et autres

Purpose To elucidate the impact of reticular pseudodrusen (RPD) on the clinical and ocular characteristics and progression rate of geographic atrophy (GA) in Japanese patients. Design Multicenter, retrospective, observational cohort study. Participants A total of 173 eyes from 173 Japanese patients (135 …

jp (code pays fourni par la source)

Short-Term Efficacy of Two-Step Treatment of Retinopathy of Prematurity in a Japanese Cohort: Anti-VEGF Therapy Followed by Routine Laser Photocoagulation

Shimpei Oba, Tatsunori Kiriishi, Masatoshi Omi, Yuki Hattori et autres

Objective: The aim of this study was to assess the efficacy of laser photocoagulation (LPC) combined with anti-vascular endothelial growth factor (VEGF), in comparison with routine LPC monotherapy, in the treatment of retinopathy of prematurity (ROP). Methods: This retrospective study included data …

jp (code pays fourni par la source)

Surgical outcomes of additional ab interno 240° suture trabeculotomy as a second surgery for patients with primary open-angle glaucoma

Hidetsugu Mori, Tatsunori Kiriishi, Masatoshi Omi, Masayuki Ohnaka et autres

jp (code pays fourni par la source)

Real-World Outcomes of Brolucizumab Treatment in Japanese Patients with Neovascular Age-Related Macular Degeneration: A 12-Month, Multicenter Study

Masayuki Ohnaka, Yoichi Sakurada, Atsushi Hayashi, Kazuaki Kadonosono et autres

INTRODUCTION: The aim of this study was to evaluate the real-world outcomes of brolucizumab use in Japanese patients with neovascular age-related macular degeneration (nAMD). METHODS: PHEASANT was a retrospective, multicenter, single-arm cohort study. The study included 438 patients, of whom 123 were …

jp, ch (code pays fourni par la source)

One-Year Outcomes of Trabeculotomy with 120°, 180°, or 360° Schlemm’s Canal Incision for Primary Open-Angle Glaucoma: A Retrospective Study

Hidetsugu Mori, Tatsunori Kiriishi, Masatoshi Omi, Masayuki Ohnaka et autres

Background/Objectives: Primary open-angle glaucoma (POAG), if caused by elevated intraocular pressure (IOP), may require a trabeculotomy (LOT), in which the trabecular meshwork (TM) and Schlemm’s canal (ISC) are incised. However, the association between the incision angle and outcomes remains unclear. Therefore, in …

jp (code pays fourni par la source)

The effect of fibroblast growth factor 2 on neovascular vessels depends on the stage of angiogenesis

Yuki Hattori, Haruhiko Yamada, Hidetsugu Mori, Kaito Yokota et autres

Objective: The exact relationship between fibroblast growth factor 2 (FGF2) and choroidal neovascularization (CNV) remains unclear. In this study, using optical coherence tomography angiography (OCTA) and FGF2-tg mice which are transgenic mice with a rhodopsin promoter/FGF2 gene fusion, we aimed to investigate …

jp (code pays fourni par la source)

Incidence and risk factors of intraocular inflammation after brolucizumab treatment in Japan: A Multicenter Age-Related Macular Degeneration Study

Satoru Inoda, Hidenori Takahashi, Maiko Maruyama-Inoue, Shoko Ikeda et autres

Purpose:To investigate the incidence of intraocular inflammation (IOI) and its risk factors following intravitreal injections of brolucizumab for neovascular age-related macular degeneration in Japan.Methods:A total of 1,351 Japanese consecutive patients with neovascular age-related macular degeneration who were treated with brolucizumab from May …